IC 300 / ZyVersa Therapeutics - LARVOL DELTA

Mechanism and structure based design of inhibitors of AMP and adenosine deaminase. (PubMed, Bioorg Med Chem) - "In a second step, binding to AMPD was further optimised via more detailed molecular modeling leading to 2-(benzyloxy)-5-(imidazo[2,1-f][1,2,4]triazin-7-yl)benzoic acid (36) (IC 300 nM). This compound does not inhibit ADA and shows excellent selectivity for plant over human AMPD."

Journal